Phenotypic plasticity of malignant T cells in blood and skin of a Sézary syndrome patient revealed by single cell transcriptomics.
Sézary syndrome
cutaneous T cell lymphoma
inflammation
malignant T cells
reactive T cells
scRNAseq
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
05
11
2022
accepted:
03
01
2023
entrez:
10
2
2023
pubmed:
11
2
2023
medline:
11
2
2023
Statut:
epublish
Résumé
Sézary Syndrome (SS) is an aggressive leukemic variant of cutaneous T-cell lymphomas (CTCL). In SS patients, malignant T cells are circulating through the blood and cause erythroderma. To compare the transcriptome of single cells in blood and skin samples from a patient with advanced SS. We utilized combined single cell RNA and T-cell receptor (TCR) sequencing (scRNA-seq). We scrutinized the malignant T cells in blood and skin in an unbiased manner without pre-sorting of cells. We observed different phenotypes of the same monoclonal malignant T-cell population, confirmed by TCR sequencing and inferred copy number variation analysis. Malignant T cells present in the circulating blood expressed genes resembling central memory T cells such as Using scRNA-seq we detected a high degree of functional heterogeneity within the malignant T-cell population in SS and highlighted crucial differences between SS cells in blood and skin.
Sections du résumé
Background
UNASSIGNED
Sézary Syndrome (SS) is an aggressive leukemic variant of cutaneous T-cell lymphomas (CTCL). In SS patients, malignant T cells are circulating through the blood and cause erythroderma.
Objective
UNASSIGNED
To compare the transcriptome of single cells in blood and skin samples from a patient with advanced SS.
Methods
UNASSIGNED
We utilized combined single cell RNA and T-cell receptor (TCR) sequencing (scRNA-seq).
Results
UNASSIGNED
We scrutinized the malignant T cells in blood and skin in an unbiased manner without pre-sorting of cells. We observed different phenotypes of the same monoclonal malignant T-cell population, confirmed by TCR sequencing and inferred copy number variation analysis. Malignant T cells present in the circulating blood expressed genes resembling central memory T cells such as
Conclusions
UNASSIGNED
Using scRNA-seq we detected a high degree of functional heterogeneity within the malignant T-cell population in SS and highlighted crucial differences between SS cells in blood and skin.
Identifiants
pubmed: 36761972
doi: 10.3389/fonc.2023.1090592
pmc: PMC9905421
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1090592Informations de copyright
Copyright © 2023 Peiffer, Gambichler, Buus, Horny, Gravemeyer, Furtmann, Spassova, Kubat, Susok, Stranzenbach, Srinivas, Ødum and Becker.
Déclaration de conflit d'intérêts
TG has received speakers and/or advisory board honoraria from BMS, Sanofi, MSD, Novartis Pharma, Janssen, Roche, Sun-Pharma, Abbvie, Almirall, Janssen, Lilly, Pfizer, Pierre Fabre, Merck-Serono, outside the submitted work. RS has received speakers and/or honoraria from Kyowa Kirin, Takeda, Novartis and Recordati Rare Diseases. LS has received speakers and/or advisory board honoraria from BMS, Sun-Pharma, MSD, and Novartis. JB is receiving speaker's bureau honoraria from Amgen, Pfizer, Recordati and Sanofi, is a paid consultant/advisory board member/DSMB member for Almirall, Boehringer Ingelheim, InProTher, ICON, Merck-Serono, Pfizer, 4SC, and Sanofi. His group receives research grants from Merck Serono, HTG, IQVIA, and Alcedis. All other authors have no conflict of interest to declare.
Références
Int J Mol Sci. 2018 Jul 24;19(8):
pubmed: 30042333
Front Immunol. 2021 Apr 21;12:666935
pubmed: 33968070
Nat Cell Biol. 2020 Jul;22(7):896-906
pubmed: 32541878
Blood. 2017 Sep 21;130(12):1468-1471
pubmed: 28760889
Sci Rep. 2017 Jun 16;7(1):3698
pubmed: 28623253
J Clin Oncol. 2010 Nov 1;28(31):4730-9
pubmed: 20855822
Blood. 2021 Dec 16;138(24):2539-2554
pubmed: 34314480
Nat Protoc. 2020 Apr;15(4):1484-1506
pubmed: 32103204
Front Immunol. 2018 Apr 30;9:863
pubmed: 29760699
Blood. 2019 Sep 26;134(13):1072-1083
pubmed: 31331920
Immunity. 2009 Jul 17;31(1):122-30
pubmed: 19592277
J Am Acad Dermatol. 2005 Dec;53(6):1093-5
pubmed: 16310082
Redox Rep. 2001;6(5):289-95
pubmed: 11778846
Database (Oxford). 2019 Jan 1;2019:
pubmed: 30951143
Mol Cancer. 2021 Sep 28;20(1):124
pubmed: 34583709
Nat Genet. 2016 Aug;48(8):838-47
pubmed: 27322546
Eur J Cancer. 2021 Oct;156 Suppl 1:S3-S4
pubmed: 34649652
Genome Res. 2019 Aug;29(8):1363-1375
pubmed: 31340985
Exp Dermatol. 2020 Oct;29(10):987-992
pubmed: 32573814
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6686-6696
pubmed: 32161126
J Immunol Res. 2018 Sep 4;2018:3930750
pubmed: 30255105
Cancer Immunol Res. 2018 Aug;6(8):900-909
pubmed: 29895574
JCI Insight. 2019 Jan 10;4(1):
pubmed: 30626755
Nat Genet. 2015 Sep;47(9):1011-9
pubmed: 26192916
Blood. 2021 Oct 21;138(16):1456-1464
pubmed: 34232982
Leuk Lymphoma. 2018 Feb;59(2):330-339
pubmed: 28595473
Genome Res. 2015 Dec;25(12):1860-72
pubmed: 26430063
J Immunol. 2008 Mar 1;180(5):2886-93
pubmed: 18292510
Sci Transl Med. 2012 Jan 18;4(117):117ra7
pubmed: 22261031
Dermatology. 2021;237(2):283-290
pubmed: 32799209
Br J Dermatol. 2021 Nov;185(5):1013-1025
pubmed: 34018188
Blood. 2010 Aug 5;116(5):767-71
pubmed: 20484084
Cancers (Basel). 2021 Apr 16;13(8):
pubmed: 33923722
Blood Adv. 2018 Aug 28;2(16):2115-2126
pubmed: 30139925
Sci Transl Med. 2015 Oct 7;7(308):308ra158
pubmed: 26446955
Immunology. 2006 Apr;117(4):433-42
pubmed: 16556256
Oncoimmunology. 2013 Jul 1;2(7):e25205
pubmed: 24073380
Science. 2016 Apr 8;352(6282):189-96
pubmed: 27124452
Cancer Discov. 2016 Sep;6(9):986-1005
pubmed: 27422033
Sci Rep. 2021 Feb 17;11(1):3962
pubmed: 33597573
Blood. 2014 Jul 31;124(5):761-70
pubmed: 24957145
J Eur Acad Dermatol Venereol. 2023 Feb;37(2):311-316
pubmed: 35993803
Proc Natl Acad Sci U S A. 2012 Dec 4;109(49):20071-6
pubmed: 23169636
Am J Clin Pathol. 2001 Jun;115(6):885-92
pubmed: 11392886